All In Biotech

Free tool

FAERS Monitor: Enflonsia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761432 or its brand name (Enflonsia, Clesrovimab-Cfor). Reports on generic versions are filed under their own applications.

Reports

13

Serious

2

15% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event5
  • extra dose administered2
  • injection site pain2
  • injection site swelling2
  • product administered to patient of inappropriate age2
  • pyrexia2
  • respiratory syncytial virus infection2
  • bacterial test positive1
  • blood culture positive1
  • influenza1
  • injection site mass1
  • medication error1
  • product dose omission issue1
  • rash1

Reports by year received

View as table
YearReports
20256
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bacterial test positive1725.9110.4180
blood culture positive1540.082.1134
product administered to patient of inappropriate age2532.1148.7596
respiratory syncytial virus infection2371.7103.9415
extra dose administered279.922.387
no adverse eventSignal544.622.4173
injection site mass143.86.710
injection site swelling242.211.845
medication error129.14.46
influenza114.52.23
injection site pain210.52.99
pyrexia29.42.68
product dose omission issue15.50.81
rash13.70.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.